IMCR – Immunocore Holdings plc ADR
IMCR — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
20.15
Margin Of Safety %
Put/Call OI Ratio
6.49
EPS Next Q Diff
0.37
EPS Last/This Y
-0.22
EPS This/Next Y
-0.19
Price
32.05
Target Price
63.98
Analyst Recom
1.56
Performance Q
-2.41
Upside
-128.9%
Beta
0.87
Ticker: IMCR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | IMCR | 33.47 | 5.42 | 0.00 | 16427 |
| 2026-03-10 | IMCR | 33.39 | 5.42 | 0.00 | 16427 |
| 2026-03-11 | IMCR | 32.44 | 5.42 | 0.00 | 16422 |
| 2026-03-12 | IMCR | 31 | 5.42 | 999.99 | 16423 |
| 2026-03-13 | IMCR | 31.04 | 5.42 | 0.33 | 16423 |
| 2026-03-17 | IMCR | 30.81 | 5.41 | 200.00 | 16433 |
| 2026-03-18 | IMCR | 30.04 | 5.41 | 200.00 | 16433 |
| 2026-03-20 | IMCR | 29.96 | 6.54 | 999.99 | 19447 |
| 2026-03-25 | IMCR | 30.38 | 6.55 | 0.03 | 19367 |
| 2026-03-26 | IMCR | 30.47 | 6.54 | 5.00 | 19371 |
| 2026-03-27 | IMCR | 29.34 | 6.54 | 999.99 | 19382 |
| 2026-03-30 | IMCR | 29.24 | 6.57 | 0.00 | 19440 |
| 2026-03-31 | IMCR | 30.14 | 6.52 | 0.71 | 19459 |
| 2026-04-01 | IMCR | 30.26 | 6.53 | 0.09 | 19430 |
| 2026-04-06 | IMCR | 31.94 | 6.49 | 1.00 | 19451 |
| 2026-04-07 | IMCR | 32.03 | 6.49 | 1.00 | 19451 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | IMCR | 33.47 | -338.0 | -120.2 | -0.89 |
| 2026-03-10 | IMCR | 33.31 | -338.0 | -116.8 | -0.89 |
| 2026-03-11 | IMCR | 32.44 | -338.0 | -112.7 | -0.89 |
| 2026-03-12 | IMCR | 31.04 | -338.0 | -109.5 | -0.89 |
| 2026-03-13 | IMCR | 30.90 | -338.0 | -116.4 | -0.89 |
| 2026-03-17 | IMCR | 30.70 | -338.0 | -117.4 | -0.89 |
| 2026-03-18 | IMCR | 30.04 | -338.0 | -96.9 | -0.89 |
| 2026-03-19 | IMCR | 30.07 | -350.9 | -97.0 | -0.93 |
| 2026-03-20 | IMCR | 29.91 | -350.9 | -96.3 | -0.93 |
| 2026-03-23 | IMCR | 30.45 | -350.9 | -98.9 | -0.93 |
| 2026-03-24 | IMCR | 29.95 | -350.9 | -96.5 | -0.93 |
| 2026-03-25 | IMCR | 30.38 | -350.9 | -98.6 | -0.93 |
| 2026-03-26 | IMCR | 30.47 | -350.9 | -99.0 | -0.93 |
| 2026-03-27 | IMCR | 29.42 | -350.9 | -93.9 | -0.93 |
| 2026-03-30 | IMCR | 29.28 | -350.9 | -93.3 | -0.93 |
| 2026-03-31 | IMCR | 30.13 | -350.9 | -97.4 | -0.93 |
| 2026-04-01 | IMCR | 30.29 | -350.9 | -98.1 | -0.93 |
| 2026-04-02 | IMCR | 30.87 | -350.9 | -100.9 | -0.93 |
| 2026-04-06 | IMCR | 31.95 | -350.9 | -106.1 | -0.93 |
| 2026-04-07 | IMCR | 32.05 | -350.9 | -101.1 | -0.93 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | IMCR | -42.01 | 4.97 | 22.58 |
| 2026-03-10 | IMCR | -42.01 | 4.97 | 22.58 |
| 2026-03-11 | IMCR | -42.01 | 4.97 | 23.83 |
| 2026-03-12 | IMCR | -42.01 | 4.97 | 23.83 |
| 2026-03-13 | IMCR | -37.25 | 4.97 | 23.83 |
| 2026-03-18 | IMCR | -34.84 | 1.32 | 23.83 |
| 2026-03-19 | IMCR | -34.84 | 1.32 | 23.83 |
| 2026-03-20 | IMCR | -34.84 | 1.32 | 23.83 |
| 2026-03-23 | IMCR | -34.84 | 1.31 | 23.83 |
| 2026-03-24 | IMCR | -34.84 | 1.31 | 23.83 |
| 2026-03-25 | IMCR | -34.84 | 1.31 | 20.15 |
| 2026-03-26 | IMCR | -34.84 | 1.31 | 20.15 |
| 2026-03-27 | IMCR | -34.84 | 1.31 | 20.15 |
| 2026-03-30 | IMCR | -34.84 | 1.31 | 20.15 |
| 2026-03-31 | IMCR | -34.84 | 1.31 | 20.15 |
| 2026-04-01 | IMCR | -34.84 | 1.31 | 20.15 |
| 2026-04-02 | IMCR | -34.84 | 1.31 | 20.15 |
| 2026-04-06 | IMCR | -27.22 | 1.26 | 20.15 |
| 2026-04-07 | IMCR | -27.22 | 1.26 | 20.15 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.6
Avg. EPS Est. Current Quarter
-0.25
Avg. EPS Est. Next Quarter
-0.23
Insider Transactions
-27.22
Institutional Transactions
1.26
Beta
0.87
Average Sales Estimate Current Quarter
107
Average Sales Estimate Next Quarter
111
Fair Value
Quality Score
51
Growth Score
45
Sentiment Score
84
Actual DrawDown %
58.4
Max Drawdown 5-Year %
-67.4
Target Price
63.98
P/E
Forward P/E
PEG
P/S
4.04
P/B
4.28
P/Free Cash Flow
EPS
-0.71
Average EPS Est. Cur. Y
-0.93
EPS Next Y. (Est.)
-1.12
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-8.88
Relative Volume
1.66
Return on Equity vs Sector %
-36.8
Return on Equity vs Industry %
-20.2
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.06
EBIT Estimation
-101.1
◆
IMCR
Healthcare
$31.96
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
56
Range 1M
56.5%
Sup Dist
1.9%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-35.2%
EPS NY
-30.1%
52W%
48.7%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+100.2% upside
Upside
+100.2%
Quality
51
Immunocore Holdings plcSector: Healthcare
Industry: Biotechnology
Employees: 524
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
IMCR
Latest News
—
Caricamento notizie per IMCR…
stock quote shares IMCR – Immunocore Holdings plc ADR Stock Price stock today
news today IMCR – Immunocore Holdings plc ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMCR – Immunocore Holdings plc ADR yahoo finance google finance
stock history IMCR – Immunocore Holdings plc ADR invest stock market
stock prices IMCR premarket after hours
ticker IMCR fair value insiders trading